EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Efficacy and Tolerability of Sodium Zirconium Cyclosilicate or Patiromer in Managing Hyperkalemia

Wannasit Wathanavasin iD, Solos Jaturapisanukul iD, Charat Thongprayoon iD, Wisit Cheungpasitporn iD

Kidney360 · 2026-07 · 7 (7) · 1601-1614

DOI: 10.34067/kid.0000001173 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Kidney360, online erschienen am 11.03.2026. Verfasst von Wannasit Wathanavasin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Nephrology Unit, Charoenkrung Pracharak Hospital, Bangkok Metropolitan Administration, Bangkok, Thailand. Hauptthemen laut MEDLINE: Hyperkalemia, Polymers, Silicates. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Key Points Both sodium zirconium cyclosilicate and patiromer effectively lower serum potassium and provide clinical benefits. Sodium zirconium cyclosilicate is associated with higher risk of edema. Patiromer is associated with the increased risk of constipation and hypokalemia.

Background

Sodium zirconium cyclosilicate (SZC) and patiromer have recently been approved for the treatment of hyperkalemia. However, their efficacy in lowering serum potassium according to the phase of intervention, safety profile, and impact clinical outcomes remains to be fully defined. This study aims to assess their efficacy and tolerability in the management of hyperkalemia.

Methods

A comprehensive search of PubMed, Scopus, and Cochrane Central Register of Controlled Trials was conducted up to June 6, 2025. Eligible studies included randomized controlled trials reporting the effects of SZC and patiromer on laboratory parameters, clinical outcomes, and safety profiles. Meta-analyses were synthesized using a random-effects model, with results presented as weighted mean differences (WMD) or relative risks (RR), along with 95% confidence intervals (CI).

Results

Nineteen randomized controlled trials involving 3627 patients (1911 on SZC; 1716 on patiromer) were analyzed. During the initial 48–72 hours, only SZC significantly reduced serum potassium levels (WMD, −0.45 mEq/L; 95% CI, –0.61 to –0.29). At the end of treatment, both agents effectively lowered serum potassium (SZC: WMD, –0.50 mEq/L; 95% CI, –0.63 to –0.38; patiromer: WMD, –0.36 mEq/L; 95% CI, –0.51 to –0.21). SZC significantly normalized serum potassium and reduced hyperkalemia incidence, while patiromer enabled renin-angiotensin-aldosterone system inhibitor optimization by supporting target dosing and reducing discontinuation due to hyperkalemia. However, SZC was associated with a higher incidence of edema (RR, 2.92; 95% CI, 1.08 to 7.90) and patiromer with increased rates of constipation (RR, 2.96; 95% CI, 1.21 to 7.22) and hypokalemia (RR, 1.46; 95% CI, 1.05 to 2.03).

Conclusions

Both SZC and patiromer effectively lower serum potassium and provide clinical benefits, with distinct safety considerations. Therapy selection should be guided by treatment goals and the patient's individual risk profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperkalemiaPolymersSilicatesHumansPotassiumRandomized Controlled Trials as TopicTreatment Outcome

Stichwörter der Autor:innen

CKDhyperkalemia

Substanzen

sodium zirconium cyclosilicatepatiromerPolymersPotassiumSilicates

Autor:innen und Institutionen

  • Department of Medicine, Nephrology Unit, Charoenkrung Pracharak Hospital, Bangkok Metropolitan Administration, Bangkok, Thailand.
  • Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
  • Nephrology and Renal Replacement Therapy Division, Department of Internal Medicine, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand.

ORCID-Profile: Wannasit Wathanavasin, Solos Jaturapisanukul, Charat Thongprayoon, Wisit Cheungpasitporn

Zitieren

APA

Wathanavasin, W., Jaturapisanukul, S., Thongprayoon, C., & Cheungpasitporn, W. (2026). Efficacy and Tolerability of Sodium Zirconium Cyclosilicate or Patiromer in Managing Hyperkalemia. Kidney360, 7(7), 1601-1614. https://doi.org/10.34067/kid.0000001173

Vancouver

Wathanavasin W, Jaturapisanukul S, Thongprayoon C, Cheungpasitporn W. Efficacy and Tolerability of Sodium Zirconium Cyclosilicate or Patiromer in Managing Hyperkalemia. Kidney360. 2026;7(7):1601-1614. doi:10.34067/kid.0000001173

BibTeX
@article{Wathanavasin2026,
  author = {Wathanavasin, Wannasit and Jaturapisanukul, Solos and Thongprayoon, Charat and Cheungpasitporn, Wisit},
  title = {Efficacy and Tolerability of Sodium Zirconium Cyclosilicate or Patiromer in Managing Hyperkalemia},
  journal = {Kidney360},
  year = {2026},
  volume = {7},
  number = {7},
  pages = {1601--1614},
  doi = {10.34067/kid.0000001173}
}
Kostenlos starten →